Compounders Research Compare

Adial Pharmaceuticals, Inc.(ADIL)

Biotechnology · Glen Allen, VA

$4.50+0.15 (+3.45%)

Delayed quote: Oct 6, 2026, 12:18 PM EDT

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Glen Allen, VA

5 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cary John Claiborne

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:20:57.499Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:20:57.499Z.

Quote observation: 2026-10-06T16:18:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 11,816,505
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 28,712,000
TTM free cash flow · period ending 2026-06-30: -11,132,946

FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ADIL EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ADIL Competitors' EV/FCF Ratio

Adial Pharmaceuticals, Inc.

Current

Market Cap

$11.82M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bullfrog AI Holdings, Inc. Common Stock

Market Cap

$11.73M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pluri Inc.

Market Cap

$11.54M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phio Pharmaceuticals Corp.

Market Cap

$11.50M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Biofrontera Inc.

Market Cap

$11.38M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kiora Pharmaceuticals, Inc.

Market Cap

$11.30M

EV/FCF Ratio

N/A

TTM Avg

5.23x

3Y Avg

5.23x

5Y Avg

5.23x

IRIDEX Corporation

Market Cap

$12.37M

EV/FCF Ratio

N/A

TTM Avg

7.58x

3Y Avg

7.58x

5Y Avg

7.58x

Cerenome, Inc.

Market Cap

$11.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioVie Inc.

Market Cap

$11.09M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dare Bioscience, Inc.

Market Cap

$12.56M

EV/FCF Ratio

N/A

TTM Avg

3.45x

3Y Avg

3.45x

5Y Avg

3.45x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Adial Pharmaceuticals, Inc. (ADIL)	$11.82M	N/A	N/A	N/A	N/A
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.73M	N/A	N/A	N/A	N/A
Pluri Inc. (PLUR)vs ›	$11.54M	N/A	N/A	N/A	N/A
Phio Pharmaceuticals Corp. (PHIO)vs ›	$11.50M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.38M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.30M	N/A	5.23x	5.23x	5.23x
IRIDEX Corporation (IRIX)vs ›	$12.37M	N/A	7.58x	7.58x	7.58x
Cerenome, Inc. (CNSY)vs ›	$11.10M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.09M	N/A	N/A	N/A	N/A
Dare Bioscience, Inc. (DARE)vs ›	$12.56M	N/A	3.45x	3.45x	3.45x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics